Loading
Biomarkers / Dementia / Diabetes Mellitus, Type 2 · Journal article
Journal of Affective Disorders · August 5, 2026
Encouraging direction, but not yet definitive.
This retrospective UK Biobank analysis identifies 41 upregulated apoptosis-related proteins in comorbid T2DM and MDD, with four proteins showing unique elevation in the comorbid state. Nine proteins were associated with dementia risk or white matter hyperintensity volumes; however, the cross-sectional proteomic design and lack of mechanistic validation limit inference about causality or clinical utility.
Retrospective cohort study with proteomic biomarker analysis. UK Biobank participants: MDD only (n=1,230), T2DM only (n=3,644), comorbid T2DM + MDD (n=721), and controls.. Intervention: No intervention; observational study of disease comorbidity and proteomic biomarkers.. Compared with: Controls (individuals without T2DM or MDD); also pairwise comparisons between single-disease and comorbid groups.. n = 15,765. UK Biobank (United Kingdom)..
Comorbid T2DM + MDD associated with 15-year dementia incidence HR = 4.44 (95% CI = [3.23, 6.11]) 41 of 60 apoptosis-related proteins significantly upregulated in comorbid T2DM + MDD relative to controls 4 proteins higher in comorbid group than in T2DM alone or MDD alone
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These findings suggest apoptosis dysregulation as a shared pathophysiological mechanism in comorbid T2DM and MDD that may contribute to dementia risk. However, peripheral protein markers require prospective validation and functional studies before informing clinical decision-making or risk stratification in routine practice.
A large retrospective cohort study identifying novel proteomic markers associated with dementia risk in comorbid T2DM and MDD, with clear statistical associations but requiring prospective validation and mechanistic confirmation.
As stated by the source record.
Quoted from the source exactly as published.
These findings suggest apoptosis dysregulation as a shared pathophysiological mechanism in comorbid T2DM and MDD that may contribute to dementia risk. However, peripheral protein markers require prospective validation and functional studies before informing clinical decision-making or risk stratification in routine practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Type 2 diabetes mellitus (T2DM) and major depressive disorder (MDD) are reciprocal risk factors, and both elevate dementia risk. Dysregulation of programmed cell death is implicated in T2DM, MDD, and neurodegeneration, but proteomic markers of apoptosis have yet to be studied as dementia predictors in people with T2DM and/or MDD. This study examines apoptosis markers in comorbid T2DM and MDD, and their associations with cognitive, dementia, and neuroimaging outcomes. The retrospective sample (n = 15,765) consisted of UK Biobank participants (MDD only n = 1230; T2DM only n = 3644; comorbid T2DM + MDD n = 721). Individuals with T2DM + MDD comorbidity had poorer cognitive performance, and a higher 15-year dementia incidence (HR = 4.44, 95% CI = [3.23,6.11]). Among 60 apoptosis-related proteins identified by Kyoto Encyclopedia of Genes and Genomes pathway enrichment, 41 were significantly up-regulated in comorbid T2DM + MDD relative to controls, and 4 were higher in the comorbid group than both T2DM alone and MDD alone. Tumor necrosis factor ligand superfamily member 10 (TNFSF10), growth arrest and DNA damage-inducible protein GADD45 beta, tumor necrosis factor ligand superfamily member 6, and RAC-gamma serine/threonine-protein kinase were associated with dementia risk. Nine proteins (e.g. apoptosis-inducing factor 1, mitochondrial, caspase-2, mitogen-activated protein kinase kinase kinase 5, TNFSF10), were associated with white matter hyperintensity volumes in comorbid T2DM + MDD after FDR correction, but none were associated with cognitive performance, atrophy, or white matter microstructural changes. These findings identify peripheral apoptosis markers that were further elevated in comorbid T2DM + MDD compared to either alone, pointing to an important pathophysiological element underlying adverse outcomes in the context of mood and metabolic comorbidity.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.